European Journal of Pediatrics

, Volume 145, Issue 1–2, pp 104–108 | Cite as

Possible polyclonal B cell activation in mucocutaneous lymph node syndrome

  • F. Furukawa
  • G. Ohshio
  • Y. Hamashima
Original Investigations

Abstract

Immunoserological studies on polyclonal B cell activation were carried out on 39 patients with mucocutaneous lymph node syndrome (MCLS) and in age-matched healthy individuals. The incidence of anti-mite, P. acnes (Kato) and EB virus antibodies, recently proposed as aetiological agents by some investigators, was increased in the patient group. Serum immunoglobulin (Ig) M level and IgM-anti-dinitrophenyl (DNP) antibodies, which are considered to be parameters of polyclonal B cell activation, were determined in MCLS cases. The level of serum IgM in MCLS was significantly elevated (0.02<P<0.05). Levels of anti-DNP antibodies in seven cases of MCLS (18%) were significantly higher than those of the controls (P<0.01). Nine of the ten pair sera in MCLS showed a stage-dependent decrease in anti-DNP antibodies. These results suggest that polyclonal B cell activation occurs in MCLS.

Key words

Mucocutaneous lymph node syndrome Polyclonal B cell activation Anti-DNP antibodies 

Abbreviations

MCLS

mucocutaneous lymph node syndrome

P. acnes

Propionibacterium acnes

EB virus

Epstein-Barr virus

D. farinae

Dermatophagoides farinae

PBS

phosphatebuffered saline

Ig

immunoglobulin

RT

room temperature

FITC

fluorescein isothiocyanate

DNP

dinitrophenyl

BSA

bovine serum albumin

OD

optical density

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Bourgois A, Kitajima K, Hunter IR, Askonas BA (1977) Surface immunoglobulins of lipopolysaccharide-stimulated spleen cells. The behavior of IgM, IgD and IgG. Eur J Immunol 7: 151–158Google Scholar
  2. 2.
    Eisen HN, Carsten ME, Belman S (1954) Studies of hypersensitivity to low molecular weight substances. III. The 2,4-dinitrophenyl group as a determinant in the precipitan reaction. J Immunol 73: 296–308Google Scholar
  3. 3.
    Fujimoto T, Kato H, Ichinose E, Sasaguri Y (1982) Immune complex and mite antigen in Kawasaki disease. Lancet ii: 980–981Google Scholar
  4. 4.
    Fujiwara H, Kao T, Shimizu J, Fujiwara T, Oo MM, Hamashima Y (1983) Microorganism in the heart in Kawasaki disease. Lancet ii: 620–621Google Scholar
  5. 5.
    Furukawa F, Oguchi M, Hashimoto M, Ohkawa S, Ozaki M, Imamura S (1982) Human Ia-like antigen expressed cutaneous T cell lymphoma associated with Epstein-Barr virus infection. Dermatologica 164: 30–35Google Scholar
  6. 6.
    Furukawa F, Kohno A, Hamashima Y (1984) Serological abnormalities in Japanese patients with borderline leprosy. Int J Lepr 52: 96–98Google Scholar
  7. 7.
    Furukawa F, Ohshio G, Ozaki M, Hamashima Y (1984) Antihapten antibodies in Japanese patients with lepromatous leprosy. Arch Dermatol Res 276: 195–198Google Scholar
  8. 8.
    Furusho K, Ohba T, Soeda T, Okabe T, Hiroto T (1981) Possible role for mite antigen in Kawasaki disease. Lancet ii: 194–195Google Scholar
  9. 9.
    Hamashima Y, Kishi K, Tasaka K (1973) Rikettsia-like bodies in infantile acute febrile mucocutaneous lymph-node syndrome. Lancet ii: 42Google Scholar
  10. 10.
    Hamashima Y, Tasaka K, Hoshino T, Nagata N, Furukawa F, Kao T, Tanaka H (1982) Mite-associated particles in Kawasaki disease. Lancet ii: 266Google Scholar
  11. 11.
    Henle G, Henle W (1966) Immunofluorescence in cells derived from Burkitt's lymphoma. J Bacteriol 91: 1248–1256Google Scholar
  12. 12.
    Hirose S, Maruyama N, Ohta K, Shirai T (1980) Polyclonal B cell activation and autoimmunity in New Zealand mice. 1. Natural thymocytotoxic autoantibodies (NTA). J Immunol 125: 610–615Google Scholar
  13. 13.
    Hirose S, Yoshida H, Ohta K, Nakai Y, Maruyama N, Shirai T (1981) Polyclonal B cell activation and autoimmunity in New Zealand mice: Anti-DNA antibodies and proteinuria. In: Shiokawa, Abe, Yamauchi (eds) New horizons in rheumatoid arthritis. Elsevier, North Holland, p 102Google Scholar
  14. 14.
    Izui S, McConahey PJ, Dixon FJ (1978) Increased spontaneous polyclonal activation of B-lymphocytes in mice with spontaneous autoimmune disease. J Immunol 121: 2213–2219Google Scholar
  15. 15.
    Japan MCLS Research Comittee (1980) Guide line for diagnosis of MCLS. Japanese Institute of Public Health, Tokyo, JapanGoogle Scholar
  16. 16.
    Kao T, Shimizu J, Furukawa F, Saito Y, Iwamoto H, Fujiwara H, Hamashima Y (1984) Reevaluation of microorganism in skin lesions in mucocutaneous lymphnode syndrome. Report of 18 cases. Acta Dermatol (Kyoto) 79: 293–298Google Scholar
  17. 17.
    Kato H, Fujimoto T, Inoue O, Kondo M, Koga Y, Yamamoto S, Shingu M, Tominaga K (1983) Variant strain of Propionibacterium acnes: A clue to the aetiology of Kawasaki disease. Lancet ii: 1383–1388Google Scholar
  18. 18.
    Kawasaki T (1967) Febrile oculo-oro-cutaneo-acrodesquamatous syndrome with or without acute nonsupprative cervical lymphadenopathy. Observations of 50 cases. Jpn J Allergy 16: 178–223 (in Japanese)Google Scholar
  19. 19.
    Kawasaki T, Kosai F, Osawa S, Shigematsu I, Yanagawa S (1974) A new infantile acute febrile mucocutaneous lymph node syndrome prevailing in Japan. Pediatrics 54: 271–276Google Scholar
  20. 20.
    Kikuta H, Mizuno F, Osato T, Konno M, Ishikawa N, Noro S, Sakurada N (1984) Kawasaki disease and an unusual primary infection with Epstein-Barr virus. Pediatrics 73: 413–414Google Scholar
  21. 21.
    Kishishita M, Yanase S, Ito Y (1982) Activation of Epstein-Barr virus expression in human lymphoblastoid P3HR-1 and Raji cells with propionic acid and with culture fluids of propionic acid-producing anaerobes. Cancer Lett 16: 117–120Google Scholar
  22. 22.
    Leung DYM, Siegel RL, Grady S, Krensky A, Maede R, Reinherz EL, Geha R (1982) Immunoregulatory abnormalities in mucocutaneous lymph node syndrome. Clin Immunol Immunopathol 23: 100–112Google Scholar
  23. 23.
    Leung DYM, Chu ET, Wood N, Grady S, Maede R, Geha RS (1983) Immunoregulatory T cell abnormalities in mucocutaneous lymph node syndrome. J Immunol 130: 2002–2004Google Scholar
  24. 24.
    Moren DM, Anderson LJ, Hurwitz ES (1980) National surveillance of Kawasaki disease. Pediatrics 65: 21–24Google Scholar
  25. 25.
    Numazaki Y, Ohmi A, Ito H (1984) Isolation of the CPE agent from two patients with Kawasaki disease. Igaku no ayumi 130: 15–16 (in Japanese)Google Scholar
  26. 26.
    Shannon K, Fink CW, Buchanan GR, Punaro M, Stastny P (1983) Lymphocyte subpopulation in Kawasaki disease. Clin Exp Rheumatol 1: 59–62Google Scholar
  27. 27.
    Sugiura A (1983) Progress in Kawasaki disease. Medico 14: 5883–5889 (in Japanese)Google Scholar

Copyright information

© Springer-Verlag 1986

Authors and Affiliations

  • F. Furukawa
    • 1
  • G. Ohshio
    • 2
  • Y. Hamashima
    • 2
  1. 1.Department of Dermatology, Faculty of MedicineKyoto UniversityKyotoJapan
  2. 2.Department of Pathology, Faculty of MedicineKyoto UniversityKyotoJapan

Personalised recommendations